Loading...
OTCM
PETV
Market cap24mUSD
Jul 09, Last price  
0.80USD
1D
-4.76%
1Q
9.22%
Jan 2017
-50.00%
IPO
100.00%
Name

PetVivo Holdings Inc

Chart & Performance

D1W1MN
OTCM:PETV chart
P/E
P/S
21.05
EPS
Div Yield, %
Shrs. gr., 5y
37.22%
Rev. gr., 5y
146.37%
Revenues
1m
+0.80%
0000075,0007,1241,51077,9363,58812,578115,586917,162968,7061,132,5331,141,607
Net income
-10m
L+24.70%
-263,440-102,630-86,210-36,992,771-1,565,692-3,651,744-15,531,533-2,337,338-4,757,758-2,114,919-3,751,375-4,941,782-8,701,764-10,955,295-8,399,166-10,473,672
CFO
-6m
L+14.76%
-172,424-49,344-70,512-219,135-398,475-690,330-143,017-579,153-736,445-496,589-1,047,329-4,174,957-6,794,483-7,419,588-5,321,953-6,107,286

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
IPO date
Jul 10, 2012
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT